Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults

Reuters

2025/06/01

Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults

Seer Inc. (Nasdaq: SEER) has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460983-en) on June 01, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540731894"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540731894\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540731894?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-01 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540731894","market":"us","top_or_hot":-1,"title":"Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Seer Inc. (Nasdaq: SEER) has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460983-en) on June 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-01 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Seer Inc. (Nasdaq: SEER) has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460983-en) on June 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL4qK97T:1","article_id":"2540731894","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540731894","pubTimestamp":1748775617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults. Seer Inc.  has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific Orbitrap Astral mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.Disclaimer: This news brief was created by Public Technologies  using generative","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4121":"生命科学工具和服务","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SEER":"Seer, Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Seer Inc.与高丽大学启动突破性的20,000个样本蛋白质组学研究，为年轻人开发人工智能驱动的癌症诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SEER":0.9},"content_text":"Seer Inc. Launches Groundbreaking 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Cancer Diagnostics for Young Adults\n    \n\n        Seer Inc. (Nasdaq: SEER) has announced the launch of a large-scale clinical study in collaboration with Korea University, aimed at identifying novel blood-based biomarkers for early cancer detection in young adults. The study will utilize Seer's newly launched Proteograph® ONE Assay and SP200 Automation Instrument, along with the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, to conduct deep, unbiased proteomic analysis of 20,000 plasma samples. This includes samples from 15,000 cancer patients and 5,000 healthy controls. The study is funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea. This initiative supports ambitious health research and seeks to develop AI-driven diagnostics for cancers in individuals in their 20s and 30s.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9460983-en) on June 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}